Back

Biatrial ablation versus left atrial ablation for atrial fibrillation treatment in patients with rheumatic heart disease undergoing valve surgery: a systematic review and meta-analysis

30 March 2025 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session 1: atrial tachyarrhythmias Clinical EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Patricia Ximenes

Albert Einstein Israelite Hospital, Sao Paulo (Brazil)

156 More presentations in this session

Presentation thumbnail
Native left atrial tachycardias clinical and electrophysiological characteristics: insights from a national survey.
Doctor S. Bun (Nice, FR)
Abstract
Presentation thumbnail
A novel immersive catheter ablation simulator based on individualized 3D MR patients' heart models improves ablation performance of future electrophysiologists.
Ms N. Bacha (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Safety and feasibility of same day discharge catheter ablation: initial German experience
Doctor S. Popescu (Luebeck, DE)
Abstract
Presentation thumbnail
Safety, obstetric and neonatal data trend of novel arrhythmia management in pregnant: zero-fluoroscopy catheter ablation vs. antiarrhythmic drugs
Doctor Z. Suleymen (Astana, KZ)
Abstract Slides Video
Presentation thumbnail
Sensor-enabled 3D electroanatomical model optimization in in-vivo porcine and benchtop models
Mr G. Wenzel (Minneapolis, US)
Abstract Slides

Access the full session

Session thumbnail
Poster session 1: atrial tachyarrhythmias

The Event

Event poster

EHRA 2025

30 March 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation recurrence following repeat catheter ablation: a systematic review and meta-analysis
thumbnail
Congress Presentation
Catheter ablation as first versus second-line therapy for atrial fibrillation: a frequentist and bayesian meta-analysis with reconstructed time-to-event and trial sequential analysis
thumbnail
Congress Presentation
Rheumatic heart disease with persistent AF: role of atrial lead in pace and ablate strategy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources